Segment, Geographical and Other Revenue Information - Concentration Risk (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Merck | Sales | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	29.00%	28.00%	47.00%
Merck | Accounts Receivable | Credit Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	37.00%	31.00%
Nestle Health Science | Sales | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	22.00%	15.00%
Nestle Health Science | Accounts Receivable | Credit Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	17.00%
Tate & Lyle | Sales | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	13.00%	11.00%
Tate & Lyle | Accounts Receivable | Credit Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage		16.00%
Novartis | Sales | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage		14.00%
Novartis | Accounts Receivable | Credit Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	11.00%	15.00%
GSK | Sales | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage			22.00%
Kyorin Pharmaceutical Co Ltd | Accounts Receivable | Credit Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	16.00%
Exela PharmSci, Inc | Accounts Receivable | Credit Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage		14.00%